Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 22, 2021 at 07:26 am EDT
Share
Wuhan Hiteck Biological Pharma Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 157.828 million compared to CNY 64.692 million a year ago. Operating income was CNY 18.090 million compared to CNY 4.003 million a year ago. Net income was CNY 14.529 million compared to CNY 4.250 million a year ago. Basic earnings per share from continuing operations was CNY 0.14 compared to CNY 0.04 a year ago.
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD 
